抗Ro52/TRIM21抗体在结缔组织病中临床作用的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (9): 1360-1365.

抗Ro52/TRIM21抗体在结缔组织病中临床作用的研究进展

严婷婷^1,2, 薛静^1*

1.浙江大学医学院附属第二医院风湿免疫科, 浙江杭州 310000;
2.嘉兴市第二医院风湿免疫科, 浙江嘉兴 314000

收稿日期:2020-04-15 修回日期:2020-10-15 出版日期:2021-09-05 发布日期:2021-09-02
通讯作者: *jingxue@zju.edu.cn

Research progress of clinical effects of anti-Ro52/TRIM21 antibody in connective tissue diseases

YAN Ting-ting^1,2, XUE Jing^1*

1. Department of Rheumatology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000;
2. Department of Rheumatology, the Second Affiliated Hospital of Jiaxing,Jiaxing 314000, China

Received:2020-04-15 Revised:2020-10-15 Online:2021-09-05 Published:2021-09-02
Contact: *jingxue@zju.edu.cn

摘要/Abstract

摘要： 抗Ro52抗体又称抗TRIM21抗体,是结缔组织病(CTD)中普遍存在的自身抗体之一。因最早在干燥综合征(SS)患者中发现,长期误认为是抗SS/Ro抗体中一个意义不明的组分。随着分子生物学技术的发展,抗Ro52抗体已正名为独立的自身抗体,然而其临床作用仍存在较多不确定。近年研究发现多种结缔组织病可独立或联合存在抗Ro52抗体导致更异质的临床特征和预后。

关键词: 抗Ro52自身抗体, 抗TRIM21自身抗体, 结缔组织病, 间质性肺炎

Abstract: Anti-Ro52 autoantibody, also known as anti-TRIM21 autoantibody, is one of the widespread autoantibodies in connective tissue diseases(CTD). It was first detected in the patients of Sjögren's syndrome(SS), which had long been considered as an unknown component of anti-SS/Ro autoantibodies. With the development of molecular biology technology, antibodies against Ro52 are considered as independent auto-antibodies. However, there is still some uncertainty about the clinical applications. Recent studies have found that various connective tissue diseases can be positive for anti-Ro52 antibodies alone or in combination with other ones, leading to clinical manifestations or prognosis heterogeneity.

Key words: anti-Ro52 autoantibody, anti-TRIM21 autoantibody, connective tissue disease, interstitial lung disease

中图分类号:

R392

严婷婷, 薛静. 抗Ro52/TRIM21抗体在结缔组织病中临床作用的研究进展[J]. 基础医学与临床, 2021, 41(9): 1360-1365.

YAN Ting-ting, XUE Jing. Research progress of clinical effects of anti-Ro52/TRIM21 antibody in connective tissue diseases[J]. Basic & Clinical Medicine, 2021, 41(9): 1360-1365.

参考文献

[1]Ogawa-Momohara M, Muro Y, Mitsuma T, et al. Clinical characteristics of anti-Ro52α and anti-Ro52β antibodies in dermatomyositis/polymyositis[J]. J Dermatol Sci, 2019, 96: 50-52.
[2]Zampeli E, Mavrommati M, Moutsopoulos HM, et al. Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations[J]. Clin Exp Rheumatol, 2020, 38: 1-8.
[3]Valor L, Schenker H, Hagen M, et al. SAT0210 the anti-Ro52 prevalence in the Sjögren's syndrome picture:a single center cross sectional study[C]. Madrid:EULAR,2019:12-15.
[4]Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies[J]. Rheumatology, 2017, 56: 999-1007.
[5]Ohashi K, Sada KE, Nakai Y, et al. Cluster Analysis Using anti-aminoacyl-tRNA synthetases and SS-A/Ro52 antibodies in patients with polymyositis/dermatomyositis[J]. J Clin Rheumatol, 2019, 25: 246-251.
[6]Li L, Wang H, Wang H, et al. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease[J]. J Neurol Sci, 2019, 397: 123-128.
[7]Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibodyassociated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response[J]. J Rheumatol, 2016, 43: 1-9.
[8]Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis[J]. Rheumatol INT, 2016, 36: 935-943.
[9]Chen F, Zuo Y, Li S, et al. Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center[J]. Respir Med, 2019, 155: 127-132.
[10]Ghirardello A, Rampudda M, Ekholm L, et al. Diagno-stic performance and validation of autoantibody testing in myositis by a commercial line blot assay[J]. Rheumatology, 2010, 49: 2370-2374.
[11]Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis[J]. Ann Rheum Dis, 2019, 78: 988-995.
[12]Patterson KA, Roberts-Thomson PJ, Lester S, et al. Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (scleroderma) cohort using principal components analysis[J]. Arthritis Rheumatol, 2015, 67: 3234-3244.
[13]Wodkowski M, Hudson M, Proudman S, et al. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival[J]. Clin Exp Rheumatol, 2015, 33: S131-S135.
[14]Priora M, Manetta T, Scarati M, et al. Serological and clinical profile of systemic sclerosis: Analysis in a cohort of patients from a single center in Northern Italy[J]. G Ital Dermatol Venereol, 2018, 153: 33-38.
[15]Liaskos C, Marou E, Simopoulou T, et al. Disease-related autoantibody profile in patients with systemic sclerosis[J]. Autoimmunity, 2017, 50: 1-8.
[16]Jorge I, Sepúlveda R, Kvarnström M, et al. Difference in clinical presentation between women and men in incident primary Sjögren's syndrome[J]. Biol Sex Differ, 2017, 8: 1-8.
[17]Budde P, Zucht HD, Vordenbäumen S, et al. Multiparametric detection of autoantibodies in systemic lupus erythematosus[J]. Lupus, 2016, 25: 812-822.
[18]Gunnarsson R, El-Hage F, Aaløkken TM, et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease[J]. Rheumatology, 2016, 55: 103-108.
[19]Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Ann Rheum Dis, 2017, 69: 9-16.
[20]Alonso-Larruga A, Bustabad S, Navarro-Gonzálvez JA, et al. Isolated Ro52 antibodies as immunological marker of a mild phenotype of undifferentiated connective tissue diseases[J]. Int J Rheumatol, 2017, 2017: 1-6.
[21]Sclafani A, D'Silva KM, Little BP, et al. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody[J]. Resp Res, 2019, 20: 2-9.
[22]Hudson M, Pope J, Mahler M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis[J]. Arthritis Res Ther, 2012, 14: 1-9.
[23]Sánchez-Montalvá A, Fernández-Luque A, Simeón CP, et al. Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study[J]. Clin Exp Rheumatol, 2014, 32: S177-S182.
[24]王超杰,姜海,夏笑笑,等.抗Ro52抗体与Ⅰ型自身免疫性肝炎患者病情的相关性研究[J].中国中西医结合消化杂志,2017,7:532-536.
[25]Salomonsson S, Dzikaite V, Zeffer E, et al. A Population-based investigation of the autoantibody profile in mothers of children with atrioventricular block[J]. Scand J Immunol, 2011, 74: 511-517.
[26]Lazzerini PE, Capecchi PL, Acampa M, et al. Anti-Ro/SSA-associated corrected QT interval prolongation in adults: the role of antibody level and specificity[J]. Arthritis Care Res, 2011,63: 1463-1470.
[27]Tangri V, Hewson C, Baron M, et al. Associations with organ involvement and autoantibodies in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG)[J]. Open J Rheumatol Autoimmune Dis, 2013, 3: 113-118.